MarketBeat on MSN4h
Gilead Sciences: 4 Reasons This Stock Has Much More To RiseCompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
Hosted on MSN1d
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...
This was the stock's third consecutive day of gains.
Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) saw some unusual options trading activity on Thursday. Stock investors bought 16,698 call options on the stock. This represents an increase of ...
Shares of Gilead Sciences ( GILD -1.77%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the ...
With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...
At the State of Black Health second annual summit hosted by BlackDoctor.org in partnership with USA TODAY, corporate leaders ...
Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.
Galapagos NV’s split could unlock value despite short-term share decline. Learn why GLPG stock’s strategic focus offers ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback